At this time, I would like to welcome everyone to the Veeva Systems fiscal 2025 fourth quarter and full-year results ...

Veeva Systems (NYSE:VEEV – Free Report) had its target price boosted by Morgan Stanley from $195.00 to $201.00 in a report ...

Veeva Systems (VEEV) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time ...

"Together with Veeva, Boehringer has advanced its approach to clinical trials and is fulfilling our pledge to accelerate the delivery of innovative, life-transforming treatments to patients across ...

Additionally, it provides analytics through Veeva Crossix, customer data via Veeva OpenData, and real-time intelligence with Veeva Link. The company also supports clinical, regulatory, and safety ...

Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time ...

Veeva disclaims any obligation to update or ... It's mostly driven by commercial and within commercial, it's Crossix. And that Crossix deceleration is mostly a function of last year's very strong ...